Bicuspid aortic valve (BAV) has been considered a relative contraindication for transcatheter aortic valve implantation (TAVI). Nevertheless, favourable results have been reported from registries and observational reports.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Transcatheter
April 29, 2017
A succinct update relevant to all arrhythmia and heart failure surgeons. The concept of atrial cardiomyopathy is particularly stimulating.
February 13, 2017
The authors report on an echocardiographic sub-study of the NOTION trial, a prospective randomized study which compared outcomes between 120 patients undergoing TAVI and 112 patients undergoing aortic valve replacement (AVR).
January 27, 2017
Results are reported of a global feasibility study in which 30 patients at high risk for mitral valve surgery were enrolled at 8 study sites. Patients underwent transapical mitral valve replacement with a Tendyne transcatheter mitral valve. A mitral prosthesis was successfully implanted in 93%.
December 27, 2016
The authors report on their findings an ongoing Japanese multicentre prospective registry. They evaluate outcomes in 478 patients undergoing transfemoral TAVI and treated with percutaneous puncture using an expandable sheath, Edwards Sapien XTprosthesis and a Perclose ProGlide system.
December 22, 2016
Sixteen patients underwent percutaneous placement of a VSD closure device for management of subarterial VSD with puncture through the chest wall and infundibulum of the RV. Fifteen were successful, and 1 patient required conversion to mini-thoracotomy for pericardial effusion and tamponade. Mean LOS was 3.5 days. No deaths, arrhythmias, valve inju
November 23, 2016
Valve in valve transcatheter aortic valve implantation (ViV-TAVI) is an alternative to redo surgical aortic valve replacement (SAVR) in inoperable patients and inpatients at high operative risk.
October 31, 2016
This single institution retrospective study evaluated outcomes of valve replacement for degenerated bioprosthetic aortic valves comparing surgical AVR (SAVR) to transcatheter valve-in-valve procedures (TViV). Patients were matched into 2 groups of 22 according to STS risk scores. Operative mortality, stroke rate, and 3-year survival were similar b
October 13, 2016
This is the first report of the use of a balloon expandable transcatheter heart valve (Edwards Sapiens 3) for TAVI in chronic aortic regurgitation (AR) involving non-calcified native valves. The authors implanted Edwards Sapiens 3 prostheses in three patients with severe AR deemed inoperable by the heart team.
September 27, 2016
This analysis of PARTNER data evaluated the impact of chronic kidney disease (CKD) on outcomes after TAVR. Patients were grouped according to GFR as none/mild, moderate, and severe renal disease. Severe disease was most common among women with diabetes.